ASCO: Enzalutamide Beneficial in Metastatic Prostate Cancer
Progression-free, overall survival longer for men with metastatic, hormone-sensitive prostate cancer
Emgality Receives First FDA Approval for Treating Cluster Headache
Patients treated with Emgality had 8.7 fewer cluster headache attacks at 3.0 weeks versus 5.2 with placebo
App Helps Pediatric Asthma Patients, Parents Self-Monitor
With one year of use, improvements seen in asthma outcomes
ASCO: Olaparib Beats Placebo for BRCA-Related Pancreatic Cancer
Progression-free survival significantly improved with olaparib versus placebo for metastatic disease
Common Supplement Ingredient Could Harm Fetus, FDA Warns
Vinpocetine is a man-made compound used in some products sold as dietary supplements
Immunizations Up in California After Repeal of Nonmedical Exemptions
At the same time, there was a sharp increase in medical exemptions in a few California counties
β-Blockers May Moderate Impact of Stress on Atrial Fibrillation
Likelihood of atrial fibrillation episode up during anger or stress; β-blockers can attenuate effect
Nonsuicidal Self-Injury Rate Up in Sexual-Minority Youth
Prevalence of NSSI ranged from 38.04 to 52.97 percent for sexual-minority youth between 2005 and 2017
Zerbaxa Approved for Hospital-Acquired Bacterial Pneumonia
Drug previously approved for treatment of complicated intra-abdominal infections, UTIs
ASCO: Survival Up With Ribociclib in Advanced Breast Cancer
OS longer for premenopausal patients receiving ribociclib in addition to endocrine therapy
